Bristol-Myers Squibb's Zenbexus flips the myeloma bet: one MRD endpoint, a 2x-to-41% hurdle

On Aug. 13, 2026, the FDA granted accelerated approval to Bristol-Myers Squibb for iberdomide (marketed as Zenbexus) in combination with daratumumab and hyaluronidase-fihj, plus dexamethasone, for adults with multiple myeloma after at least one prior line that included both a proteasome inhibitor and an immunomodulatory agent.

Because this is an accelerated approval, the economic “reset” case hinges less on today’s label and more on whether the confirmatory trial sustains—and broadens—the early MRD signal into clinical benefit that pays through payer adoption and sequencing.

The FDA’s coverage ties Zenbexus to the regimen’s core structure: an oral CELMoD backbone (iberdomide) combined with daratumumab (administered subcutaneously in the protocol via daratumumab/hyaluronidase) and dexamethasone. In practical market terms, that matters because payers and physicians will evaluate whether Zenbexus drives distinct outcomes versus switching friction away from existing daratumumab-based standard-of-care pathways.

Revlimid (lenalidomide) is the myeloma workhorse whose long-term economics are pressured by patent timing and competition. Zenbexus is positioned as a CELMoD therapy—built to engage cereblon—so the investor question becomes whether iberdomide can be adopted as a functional successor for patients whose prior treatments and resistance patterns make “Revlimid-like” next steps less reliable.

Zenbexus is an oral agent, so its near-term bottleneck tends to be less on infusion capacity and more on drug substance/drug product throughput, REMS-enabled dispensing, and distribution to certified prescribers. That doesn’t automatically limit long-term growth—but it can influence whether the first quarters after launch under-supply demand and delay script-driven revenue.

On the regimen side, daratumumab/hyaluronidase is already a major myeloma backbone for multiple companies’ portfolios. The supply-chain implication is that competitive differentiation may show up faster in “who wins the oral partner slot” than in the broader drug-filling capacity of anti-CD38 therapy—meaning iberdomide’s rollout can be gated by programmatic access and patient selection, not just physical supply.

The brief frames a market worry: iberdomide could simply be another addition behind Johnson & Johnson’s Darzalex ecosystem. The FDA language pushes the story in a more specific direction: Zenbexus’s regulatory moment is explicitly tied to improving MRD-negative complete response when added into the daratumumab/hyaluronidase + dexamethasone platform.

Zenbexus matters to the equity narrative not because it instantly fixes corporate growth, but because it provides a late-cycle probability of sustaining myeloma franchise value through sequencing transitions. The practical investor read: if iberdomide’s confirmatory work converts the MRD endpoint into coverage-grade outcomes, it can extend the “platform contribution” expected from BMS’s portfolio during patent-window uncertainty.